Formulated to please patients—and dermatologists
Patient self-assessment: 68% reported improvement1
As reported in 2 double-blind, randomized, controlled studies of 2813 patients with moderate to severe acne:
Following 12 weeks of treatment, 68% of adolescents treated with Acanya Gel in pivotal studies rated their acne as "clear," "almost clear," or having "marked improvement"
High completion rate
- 91% of patients treated with Acanya Gel completed the 12-week studies, as shown in 2 double-blind, randomized, controlled studies of 2813 patients with moderate to severe acne1
Elegant aqueous gel formulated to enhance patient experience
- No alcohol, surfactants, parabens, or preservatives
- Fragrance-free gel goes on smoothly, disappears quickly, and leaves no residue
- Can be used under makeup and sunscreen
Reference: 1. Pivotal studies data on file, CORIA Laboratories.
Indication and Important Safety Information: Acanya Gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. Do not prescribe if the patient has shown hypersensitivity to clindamycin, benzoyl peroxide, or to lincomycin. Acanya Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Discontinuation is recommended if significant diarrhea, bloody diarrhea, severe abdominal cramping, or colitis (including pseudomembranous colitis) develops. Clindamycin taken orally or through IV may result in severe colitis, which may result in death. Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately. Patients should be advised to avoid contact with the eyes or mucous membranes and to minimize sun exposure following the application of Acanya Gel. In controlled clinical trials, the following application-site adverse reactions occurred in less than 0.2% of patients treated with Acanya Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and application site irritation (0.1%).
